Skip to main content

Advertisement

Log in

Novel notions on newborn lung disease

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Many premature infants have deficient pulmonary surfactant, which is required to reduce surface tension and prevent lungs from collapsing. A recent study may provide a new avenue for therapy by showing that vascular endothelial growth factor (VEGF) helps to regulate surfactant production. When given to premature mice near birth, VEGF can reduce symptoms of surfactant deficiency and relieve respiratory distress (pages 702–710).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1

Coutesy of Veerle Compernoole

Figure 2: The VEGF receptor Flk-1 (blue) and its transcriptional activator HIF-2α (green) are expressed in surfactant-producing cells (identified by alkaline phosphatase, red).

Coutesy of Till Acker

References

  1. Pattle, R.E. Properties, function and origin of the alveolar lining layer. Nature 175, 1125–1126 (1955).

    Article  CAS  Google Scholar 

  2. Clements, J.A. Surface tension of lung extracts. Proc. Soc. Exp. Biol. Med. 95, 170–172 (1957).

    Article  CAS  Google Scholar 

  3. Avery, M.E. & Mead, J. Surface properties in relation to atelectasis and hyaline membrane disease. Am. J. Dis. Child 97, 517–523 (1959).

    CAS  Google Scholar 

  4. Liggins, G.C. Premature delivery of foetal lambs infused with glucocorticoids. J. Endocrinol 45, 515–523 (1969).

    Article  CAS  Google Scholar 

  5. Liggins, G.C. & Howie, R.N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 50, 515–525 (1972).

    CAS  PubMed  Google Scholar 

  6. Fujiwara, T. et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1, 55–59 (1980).

    Article  CAS  Google Scholar 

  7. Compernolle, V. et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, while treatment with VEGF prevents fatal respiratory distress in premature mice. Nature Med 8, 702–710 (2002).

    Article  CAS  Google Scholar 

  8. Bland, R.D. & Nielson, D.W. Developmental changes in lung epithelial ion transport and liquid movement. Annu. Rev. Physiol. 54, 373–394 (1992).

    Article  CAS  Google Scholar 

  9. Northway, W.H. Jr et al. Late pulmonary sequelae of bronchopulmonary dysplasia. New Engl. J. Med. 323, 1793–1799 (1990).

    Article  Google Scholar 

  10. Coalson, J.J. Pathology of chronic lung disease of early infancy. in Chronic Lung Disease in Early Infancy. Vol. 137 of Lung Biology in Health and Disease. (series; eds. Bland, R.D. & Coalson, J.J.) 85–124 (Marcel Dekker Inc., New York, 2000).

    Google Scholar 

  11. Bhatt, A.J. et al. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, flt-1, and tie-2 in human infants dying with bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 164, 1971–1980 (2001).

    Article  CAS  Google Scholar 

  12. Coalson, J.J., Winter, V.T., Siler-Khodr, T. & Yoder, B.A. Neonatal chronic lung disease in extremely immature baboons. Am. J. Respir. Crit. Care Med. 160, 1333–1346 (1999).

    Article  CAS  Google Scholar 

  13. Albertine, K.H. et al. Chronic lung injury in preterm lambs. Disordered respiratory tract development. Am. J. Respir. Crit. Care Med. 159, 945–958 (1999)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rabinovitch, M., Bland, R. Novel notions on newborn lung disease. Nat Med 8, 664–666 (2002). https://doi.org/10.1038/nm0702-664

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0702-664

  • Springer Nature America, Inc.

Navigation